Prescription Treatment for Keloids
Intralesional triamcinolone acetonide (10-40 mg/mL) is the first-line prescription therapy for keloids, with triamcinolone-40 specifically recommended for hypertrophic scars and keloids 1. This represents the most established and guideline-supported treatment approach.
Primary Treatment Algorithm
First-Line Therapy
- Intralesional triamcinolone acetonide 10-40 mg/mL injected directly into the keloid
Important Caveat: Local overdose can cause atrophy, pigmentary changes, telangiectasias, and hypertrichosis 1. Careful dosing is essential to avoid these complications.
Contraindications to Intralesional Corticosteroids
Do not inject at sites with:
- Active infections (impetigo, herpes)
- Previous hypersensitivity to triamcinolone
- Active tuberculosis or systemic fungal infection (for large injections)
- Active peptic ulcer disease
- Uncontrolled diabetes, heart failure, or severe hypertension
- Severe depression or psychosis 1
Enhanced Combination Therapies
When triamcinolone monotherapy fails or for more aggressive treatment:
Most Evidence-Supported Combination
Triamcinolone + 5-Fluorouracil (9:1 dilution) shows the strongest and most consistent evidence for keloid treatment 2, 3. This combination demonstrates:
- Increased efficacy compared to triamcinolone alone
- Similar or fewer adverse events than monotherapy
- Superior results specifically for keloids 3
Alternative Adjuvant Agents
Consider adding to triamcinolone:
- Bleomycin (intralesional) - mixed results but can be effective 4
- Verapamil (intralesional) - mixed results reported 4
- Botulinum Toxin A - emerging evidence as adjuvant 2
Note: 5-FU combined with triamcinolone has the most robust evidence base among all combination therapies 2.
Location-Specific Considerations
Non-Auricular Keloids
Intralesional triamcinolone + intralesional cryotherapy produces the most promising results and should be considered first-line 5.
Auricular Keloids
If surgical intervention is chosen, surgical excision + compression therapy achieves superior results for ear keloids 5.
Refractory Keloids
For keloids that fail initial therapies:
Post-Excision Radiotherapy
- Soft X-ray radiotherapy: 12 Gy in 6 sessions immediately post-excision 6
- 50% non-recurrence rate within 2 years 6
- Critical Warning: Previously treated keloids (especially with topical steroids or 5-FU) have significantly higher recurrence rates - 69.2% of relapsed cases had prior treatment 6
- Expect hyperpigmentation in 34% of patients, particularly in non-Caucasian patients (61.3%) 6
Laser Therapy
Can be combined with intralesional corticosteroids or topical steroids with occlusion to improve drug penetration 4. Ablative laser and pulsed-dye laser show the most utility 3.
Skin Type Consideration: Laser treatment response is significantly linked to Fitzpatrick skin type (p=0.002), with better outcomes in types I-III compared to IV-VI 3.
Prevention Strategy
Prevention remains superior to treatment 7. For patients with keloid history or family history:
- Avoid unnecessary skin trauma and procedures 8
- The outcome is uncertain whenever there is trauma to the skin resulting in scar 8
- Counsel patients that body modifications (piercings, tattoos, scarification) carry unpredictable keloid risk 8
Adjunctive Therapies
Silicone-Based Products
Silicone gel or sheeting with corticosteroid injections is supported as first-line therapy 4. Silicone sheeting also has evidence for reducing keloid recurrence post-treatment 4.
Pressure Therapy
Has evidence for reducing keloid recurrence and can be used adjunctively 4.
Treatment Efficacy Hierarchy
Based on systematic review evidence 3:
- Intralesional injection: 64.1% mean reduction in scarring [95% CI 60.8-67.5%]
- Topical treatments: 34% mean reduction [95% CI 31.8-36.8%]
- Physical treatments: 29.9% mean reduction [95% CI 28.9-30.9%]
This clearly demonstrates intralesional therapy as the most effective modality.
Critical Clinical Pitfalls
Prior treatment reduces success: Keloids previously treated with topical therapies (steroid injections, 5-FU) have the highest recurrence rates with subsequent interventions 6
Repeated injections risk systemic effects: Multiple corticosteroid injections can suppress the hypothalamic-pituitary-adrenal axis 1
Anaphylaxis risk: Though rare, anaphylaxis, angioedema, and urticaria can occur with intralesional corticosteroids 1
Contact dermatitis: The preservative benzyl alcohol in some formulations can cause allergic contact dermatitis 1